Last update 08 May 2025

KAHR-103

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
CD40-FasL (KAHR)
Target
CD40L x FasR
Action
stimulants
Mechanism
CD40L stimulants(CD40 ligand stimulants), FasR stimulants(Apoptosis-mediating surface antigen FAS stimulants)
Therapeutic Areas
Immune System Diseases
Active Indication-
Inactive Indication
Autoimmune Diseases
Originator Organization
KAHR Medical Ltd.KAHR Medical Ltd.
Active Organization-
Inactive Organization
KAHR Medical Ltd.KAHR Medical Ltd.
License Organization-
Drug Highest PhasePendingDiscovery
First Approval Date-
Regulation-

Related

100 Clinical Results associated with KAHR-103
Login to view more data
100 Translational Medicine associated with KAHR-103
Login to view more data
100 Patents (Medical) associated with KAHR-103
Login to view more data
100 Deals associated with KAHR-103
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autoimmune DiseasesDiscovery
Israel
KAHR Medical Ltd.KAHR Medical Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free